Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Memory Impairment
Conditions
Memory Impairment, Alzheimer's Disease
Trial Timeline
Jan 1, 2014 → May 1, 2014
NCT ID
NCT02051335About Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine
Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine is a phase 1 stage product being developed by AstraZeneca for Memory Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT02051335. Target conditions include Memory Impairment, Alzheimer's Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02051335 | Phase 1 | Completed |
Competing Products
8 competing products in Memory Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 85 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 51 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 84 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| Piracetam | UCB | Pre-clinical | 20 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |